Metabolix Bundle

Three vials from metabolic research: tirzepatide (the molecule in Mounjaro and Zepbound, a GIP and GLP-1 receptor agonist), tesamorelin (the molecule in Egrifta, a GHRH analog) and AOD-9604 (a modified growth hormone fragment studied in fat-metabolism research). The catalog states no rationale, and the three have never been studied together. Neither approved molecule is offered here in its approved form.

In SURMOUNT-1, tirzepatide arms reported average weight reductions of 15.0–20.9% over 72 weeks, with about a quarter of the loss lean mass in a DXA substudy. Tesamorelin cut visceral fat 15–18% over 26 weeks in HIV patients, with lean mass up about 1.2–1.3 kg; fat returned after stopping. AOD-9604 increased fat breakdown in obese mice, but its largest human trial (502 randomized, oral, 24 weeks) missed its weight-loss endpoint. No study has tested these together.

Tirzepatide lowers blood sugar while tesamorelin's label warns of glucose intolerance, so the net effect is unpredictable, especially with diabetes or prediabetes; both labels also flag diabetic eye disease. Tesamorelin raised IGF-1 well above normal in many trial participants and is contraindicated with active cancer; tirzepatide carries a boxed warning for rat thyroid C-cell tumors. Tirzepatide's nausea (25–29% vs 8%) and fluid loss contrast with tesamorelin's fluid retention, and AOD-9604 showed liver changes in monkeys.

AOD-9604 is approved for no use, and FDA advisers voted 12–0 against compounding it. Tirzepatide is approved only as Mounjaro and Zepbound, and FDA has warned sellers of research-use tirzepatide marketed for people; tesamorelin is approved only as Egrifta products to reduce excess abdominal fat in HIV-related lipodystrophy and, as a biologic, cannot be compounded. AOD-9604 and tesamorelin are prohibited at all times by WADA; tirzepatide is permitted and monitored.